Skip to content

A study comparing tranexamic acid plus oxytocin with oxytocin alone in reducing blood loss during planned caesarean section.

Comparison of the effects of prophylactic tranexamic acid plus oxytocin versus oxytocin alone in reducing blood loss during elective caesarean section.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
PACTR
Registry ID
PACTR202605854303695
Enrollment
156
Registered
2026-05-18
Start date
2026-06-01
Completion date
Unknown
Last updated
2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pregnancy and Childbirth

Interventions

Sponsors

Ani Frank Onyeka
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: Women with singleton pregnancies at 37 to 40 weeks gestational age scheduled for elective caesarean section. Para 1 to 4. Women who provide written informed consent. Women aged 20–40 years.

Exclusion criteria

Exclusion criteria: Women with known bleeding disorders or coagulation abnormalities, A history of thromboembolic disease, Severe medical conditions such as hepatic or renal impairment, liver pathology, hypertensive disorders in pregnancy, antepartum haemorrhage. Known hypersensitivity to oxytocin or tranexamic acid, or those undergoing emergency caesarean section, Women who do not consent will be excluded.

Design outcomes

Primary

MeasureTime frame
Primary outcome measure will be the mean intraoperative blood loss (mL) between the two groups

Secondary

MeasureTime frame
secondary outcomes will include the incidence of excessive blood loss (defined as blood loss =1000 mL intraoperatively). the mean change in haematocrit levels, need for additional uterotonic agents or blood transfusion, and maternal drug adverse events such as nausea, vomiting, hypotension, thromboembolic events.

Countries

Nigeria

Contacts

Public ContactCHIKA JOYCE EZEUGO

Chief Consultant Obstetrician and Gynaecologist

joyce_chychy@yahoo.com+2348039484764

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026